Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Mark Your Calendars! | UMR's 2025 Annual Report is Coming Soon!
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Mark Your Calendars! | UMR's 2025 Annual Report is Coming Soon!
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Study suggests those who had COVID-19 may only need one vaccine dose
People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but little immune benefit after the second dose, according to new research from the Penn Institute of Immunology. The findings, published in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response. The team found that those who did not have COVID-19—called COVID naïve—did not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.